Law arylsulfatase A levels are reported in two siblings, one with a neurologic disability not typical for metachromatic leukodystrophy, the other a healthy 18-year-old female with a normal developmental history. In both individuals, arylsulfatase A levels in white blood cells were 7-846 of control values. Cultured fibroblasts gave low values (8-10% of normal) for both cerebroside sulfatase and arylsulfatase A activities. Other family members had enzyme levels consistent with heterozygote or normal status. Cerebroside sulfate loading tests of cultured fibroblasts in 19PCOs media were normal for all family members who were tested. In MEM-HEPES media, however, cells from the two arylsulfatase A deficient siblings showed attenuated sulfolipid catabolism.
a neurologic disability not typical for metachromatic leukodystrophy, the other a healthy 18-year-old female with a normal developmental history. In both individuals, arylsulfatase A levels in white blood cells were 7-846 of control values. Cultured fibroblasts gave low values (8-10% of normal) for both cerebroside sulfatase and arylsulfatase A activities. Other family members had enzyme levels consistent with heterozygote or normal status. Cerebroside sulfate loading tests of cultured fibroblasts in 19PCOs media were normal for all family members who were tested. In MEM-HEPES media, however, cells from the two arylsulfatase A deficient siblings showed attenuated sulfolipid catabolism.
Additional c b k a l and laboratory studies on these individuals failed to demonstrate any features suggestive of metachromatic leukodystrophy, ie., normal nerve conduction velocities, normal surd nerve biopsy results, and normal urinary sulfatide excretion. It is concluded that the neurologic abnormalities in the one sibling are not the result of the low enzyme activity and that both individuals represent examples of pseudo arylsulfatase A deficiency (arylsulfatase A deficiency without metachromatic leukodystrophy). These results thus call into question the ability of the high-sensitivity cerebroside sulfate loading test as carried out in MEM-HEPES media to differentiate pathologically signir~cant defects ie., metachromatic leukodystrophy from benign "pseudodeficiencies." Abbreviations MEM-HEPES, minimum essential medium-N*-2-hydroxyethylpiperazine-N*ethanesuIfonic acid MLD, metachmatic leukodystrophy pd/mld, pseudodeficiency/metachromatic leukodystrophy compound heterozygote
In 1963 Austin et 01. (2) demonstrated that patients with metachromatic leukodystrophy lacked arylsulfatase A. Subsequently, Mehl and Jatzkewitz (16) showed that arylsulfatase A was the heat labile component of cerebroside sulfatase. In most individuals lacking this enzyme, cerebroside sulfate cleavage is blocked, cerebroside sulfate accumulates and the clinical picture of metachromatic leukodystrophy evolves over a period of time (17) . Since these early observations, many investigators have provided evidence for biochemical, clinical and/or genetic heterogeneity in various subjects lacking arylsulfatase A; thus, metachromatic leukodystrophy can currently be subdivided into at least three distinct types, i.el, late infantile, juvenile and adult (9, 17) . Furthermore, there ha e been several reports of individuals having very low arylsulfa 7 ase A levels but who nevertheless lack clinical features characte(nstic of metachromatic leukodystrophy (4, 5,6,7, 11, 14, 25). Kih a et 01.
(1 1) have wined the term "pseudo arylsulfatase A defici ' d ncv" to describe these subiects whereas others have ;designation "arylsulfatasd A deficiency without metleukodystrophy." Current data indicate that this is a benign v * t havbg no direct medical consequences (9) . do arise, however, as arylsulfatase A and els are very low in both the various forms ' arylsulfatase A deficiency. It is often matic grounds, to distinguish between these s. As a result of this problem, Fluharty et al. subsequent regression in developmental milestones were noted. A decreased rate of head mowth was also documented. After 2 vears of age, she began sloGly to gain additional developmenti and motor milestones. Examinations at 2% years of age revealed microcephaly, hypotonia, and psychomotor retardation. Her EEG was mildly abnormal with occasional seizure discharges. Extensive evaluation failed to reveal any infective, metabolic, neoplastic, or vascular causes for her disorder. Subject 11-2 (see Fig. 1 ) is an 18-year-old healthy female of at least normal intelligence and athletic ability. The remaining members of the immediate family are healthy and of at least normal intelligence.
MATERIALS AND METHODS
Fibroblast cultures were established from skin biopsies obtained from the five sibs, their parents, and controls as previously described (13, 23, 24) . Arylsulfatase A activity in fibroblasts was measured with 4nitrocatechol sulfate according to a modification (24) of the method of Baum et al. (3). Cerebroside sulfatase activity was assayed with [3H]cerebroside sulfate by the method of Raghaven et al. (22) . Urinary sulfatide levels were measured by high performance liquid chromatography of benzoyl derivatives as described by Nonaka and Kishimoto (18) .
Cerebroside sulfate loading tests were carried out by incubating cells with [=S]-labeled rat brain cerebroside sulfate as described by Kihara et al. (1 I) . Loading experiments designated "199-COT were carried out in medium 199 with Earles salts, 26 mM NaHC03 and 10% serum in an atmosphere of 5% CCOz-95% air (1 1). Experiments labeled "MEM-HEPES" were performed on cells incubated in MEM-HEPES as described by Fluharty et al. (8) .
RESULTS
Sonicates of cultured fibroblasts from 11-2 and 11-5 had aryhulfame A levels that were 10 and 8% respectively, of control values (Table 1) . Cells from sib II-1 and the parents (1-1 and 1-2) contained levels that were 67,s 1 and 48%, respectively, of normal.
Arylsulfatase A activities of cell sonicates of sibs 11-3 and 11-4 were in the range of control cells (Table 1) . Similar, but somewhat lower, results were obtained witb leukocyte preparations (Table  1) .
Cerebroside dfhtase activities in fibroblast sonicates of these individuals against ['Hj-labeled cerebroside sulfate are summarized in Table 1 . Again, cells from subjects 11-2 and 11-5 had low levels whereas sib IEl and the parents had intermediate levels.
The ability of subjects 1-1, 1-2, 11-2, and 11-5 to metabolize cerebroside sulfate was also examined by cultwing intact fibroblasts in media containing [sS]-labeled substrate for 2, 4, and 6 days. These loading tests were carried out in two media: in the usual 199-C02 and in a MEM-HEPES system, which tends to be more sensitive to margioal cerebroside sulfatase function. In the 199-C02 system, fibroblasts from both 11-2 and 11-5 degraded the labeled sulfolipid in a nearly normal manner (Fig. 2) . In MEM-HEPES, a distinct impairment in the ability to degrade cerebroside sulhte was evident in both enzyme deficient cell lines (Fig. 3) .
The impairment was most severe in cells from the normal subject 11-2, falling into a range more or less typical of juvenile or adult MLD cells in this medium. The defect in the neurologically impaired subject 11-5 was less striking and was in the range encountered with pseudo-deficiency cell lines. Fibroblasts from I-1 and 1-2 were indistinguishable from controls in both media.
DISCUSSION
These studies demonstrate that subjects 11-2 and 11-5 have low levels of both arylsulfatase A and cerebroside sulfatase activities; moreover, intermediate levels of these activities in the cells of the parents and one sib indicate that the alterations are inherited in an autosoma1 recessive manner. Additional investigations of subjects 11-2 and 11-5 failed to provide any evidence indicating that these enzyme deficiencies had any direct clinical consequences. Although patient 11-5 suffers from psychomotor retardation, microcephaly, and hypotonia, she nevertheless lacks any clinical or biochemical abnormalities compatible with any form of metachromatic leukodystrophy. Swcally, the following procedures yielded normal results: measurement of nerve conduction velocities, analysis of cerebrospinal fluid protein, ophthalmologic examination, computed cerebral tomography and brainstem auditory evoked responses. In addition, microscopy of plastic-embedded sections of a swal nerve biopsy which were stained with toluidine blue, showed no evidence of demyelination, axonal loss, or cell inclusion.
Normal levels of sulfatides in the urine of both 11-2 and 11-5 (see Table 1 ) also provide direct evidence that these individuals, in contrast to MLD patient (19) , are capable of metabolizing cerebroside sulfates in a normal fashion. The normal development of subject 11-2 also supports this conclusion. We can not rule out the possibility of an adult or a variant form of metachromatic leukody&rophy &i the preclinical stage existing in either of these sibs: however. the results of the additional laboratory procedures make this a very unlikely possibility. Preclinical forms of adult metachromatic leukodystrophy would be expected to have increased levels of urinary sulfatides (20) , abnormal surd nerve biopsy results (I), and decreased nerve conduction times (20) . all of which are normal in these individuals.
Until now &e sdfatide loading test has been an accurate means of distinguishing between "pseudo" deficiency and the various clinical forms of MLD. The sensitivity of the test to marginal cerebroside sulfatase function is enhanced when MEM-HEPES rather than the original 199-C02 system (21) is employed (12) . Normal individuals with low arylsulfatase A activities have, heretofore, been nearly indistinguishable from controls in either growth media. A diminution of cerebroside sulfate clearance capacity in "pseudo"-deficient cell lines has been seen in MEM-HEPES, but clearance of less than half the assimilated sulfolipid has only been encountered in neurologically impaired individuals.
Even though subjects 11-5 might be included in this category, subject 11-2 cannot. A clear depression of cerebroside sulfate catabolism in cells cultured MEM-HEPES occurs without any indication of neurologic compromise or aberrant in vivo sulfolipid metabolism in the intact individual. Furthermore, there appears to be no association between low arylsulfatase A activity, the moderate cerebroside sulfate clearance defect in MEM-HEPES and the "non-MLD neurologic abnormality in subject 11-5. clinical status. basis of the f111dings reported here remains unadditional clues as to the biologic alterathe various forms of MLD as well as the "pseudo"-defident state. Furthermore, they strongly indicate the need for carefu0, consideration of culture conditions when utilizing the arebrosid sulfate loading procedure for either diagnostic or investigative s %i dies. The occurrence of severe neurologic problems in m appluently "pseudo9'-deficient individual does call the benign nature of the pseudodeficiency state into question. At present this mwt be regarded as a fortuitous association, but if additional exqples are found in the future, one would have to consider the ppsibility of some sort of increased risk for such individuals. 
